
    
      This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy,
      safety, tolerability, in subjects with FRDA following the oral administration of study drug
      (active or placebo capsules). Sixty eligible patients will undergo various assessments at
      different time points during the the study. The study duration is 13 months which includes
      screening, treatment and safety follow up phone call.
    
  